← Back to Search

Vaccine

Vivotif Vaccine for Typhoid Risk Reduction

Phase 4

Recruiting

Research Sponsored by University of Maryland, Baltimore

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18 years and older

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up approximately 5 years

Awards & highlights

Study Summary

This trial will study how well the typhoid vaccine works in adults, and how long the immunity from the vaccine lasts. Blood, saliva, and stool samples will be collected from participants over 8 years to help researchers understand how the vaccine works.

Who is the study for?

Adults over 18 in good health can join this trial. They must not have heart disease, active ulcers, intestinal conditions, recent anemia treatment, substance abuse issues, diabetes or recent cancer (except certain skin and cervical cancers). Blood tests will exclude those with abnormal blood counts or liver function, hepatitis B/C or HIV infections. Pregnant women and those on anti-malarial drugs cannot participate.Check my eligibility

What is being tested?

The study involves the Vivotif typhoid oral vaccine already approved for travelers to certain countries. Participants will receive the vaccine and provide blood, saliva, and stool samples for up to eight years to help researchers understand how it protects against other similar diseases.See study design

What are the potential side effects?

While specific side effects are not listed here for Vivotif typhoid oral vaccine within this trial context; generally such vaccines may cause stomach pain, nausea, fever, headache or rash.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ approximately 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~approximately 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percentage of Responders

Trial Design

1Treatment groups

Experimental Treatment

Group I: Vaccination with Oral Typhoid Vaccine (Vivotif)Experimental Treatment1 Intervention

Volunteers receive immunization with Vivotif oral typhoid vaccine. Blood, saliva, and stool specimens are collected at subsequent visits.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Maryland, BaltimoreLead Sponsor

688 Previous Clinical Trials

374,506 Total Patients Enrolled

2 Trials studying Risk Reduction

178 Patients Enrolled for Risk Reduction

Media Library

Vivotif Typhoid Oral Vaccine (Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT03971669 — Phase 4

Risk Reduction Research Study Groups: Vaccination with Oral Typhoid Vaccine (Vivotif)

Risk Reduction Clinical Trial 2023: Vivotif Typhoid Oral Vaccine Highlights & Side Effects. Trial Name: NCT03971669 — Phase 4

Vivotif Typhoid Oral Vaccine (Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03971669 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you provide a summation of the research conducted surrounding Vivotif Typhoid Oral Vaccine?

"Presently, 4 clinical trials are being conducted on Vivotif Typhoid Oral Vaccine. These tests have yet to reach Phase 3 status and primarily take place in Baltimore, Maryland with additional research centres located elsewhere."

Answered by AI

Are there any open vacancies for this clinical experiment?

"As per the clinicaltrials.gov webpage, this research program is presently enlisting participants; it was originally published on January 16th 2004 and updated most recently on November 9th 2022."

Answered by AI

What is the uppermost limit of participants in this medical experiment?

"Affirmative. The clinical trial information available on clinicaltrials.gov confirms that recruitment is currently underway for this medical study, which was first posted on January 16th 2004 and most recently updated November 9th 2022. A total of 150 patients are needed to be recruited from 1 site."

Answered by AI

Has the Vivotif Typhoid Oral Vaccine been granted FDA approval?

"As this medication is approved, there has been a plethora of supportive data regarding its safety and efficacy; thus, Vivotif Typhoid Oral Vaccine was awarded a rating of 3."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Blood Donor CVD 5000

Wilbur Chen, MD, MS 2004. "Blood Donor CVD 5000". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03971669.